Physician profile
Ermal Molla
NPI 1902163975
$4,639.18
in general payments reported to CMS, 2019-2025
29 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $248 · 2021: $917 · 2022: $817 · 2023: $1,217 · 2024: $115 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $962.47 | 2019-2023 | Enbrel, Tavneos, Prolia |
| Abbvie INC. | $737.11 | 2019-2025 | |
| Lilly USA, LLC | $362.92 | 2019-2025 | Taltz, Zepbound |
| Ucb, INC. | $288.96 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $266.65 | 2019-2025 | |
| Janssen Biotech, INC. | $230.14 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $222.13 | 2019-2023 | Benlysta |
| Pfizer INC. | $221.83 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $198.02 | 2021-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $154.48 | 2021-2023 | Acthar |
| Genzyme Corporation | $117.45 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $116.00 | 2022-2023 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $105.50 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.37 | 2019-2021 | |
| Bioventus LLC | $96.03 | 2019-2023 | Durolane |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $74.01 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $56.88 | 2021 | |
| Fresenius Kabi USA, LLC | $47.72 | 2023 | Idacio |
| Genentech USA, INC. | $41.54 | 2019 | |
| Mallinckrodt Enterprises LLC | $41.04 | 2019 | |
| Sandoz INC. | $38.62 | 2023 | Hyrimoz |
| Horizon Therapeutics Plc | $34.40 | 2020-2022 | |
| Radius Health, INC. | $23.13 | 2019 | |
| Depuy Synthes Sales INC. | $20.42 | 2023 | Monovisc |
| Kiniksa Pharmaceuticals, LTD. | $19.03 | 2023 | Arcalyst |
| Almatica Pharma LLC | $18.48 | 2023 | Gralise |
| Celgene Corporation | $17.02 | 2019 | |
| Sobi, INC | $16.53 | 2022 | |
| Medexus Pharma, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ermal Molla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.